Truist Financial Corp Kazia Therapeutics LTD Transaction History

Truist Financial Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 22, 2022	SELL	$6.05 - $8.65 $190,091 - $271,783	-31,420 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$7.35 - $12.0 $17,640 - $28,800	2,400 Added 8.27%	31,420 $264,000
Q2 2021 Aug 16, 2021	BUY	$9.1 - $14.71 $9,100 - $14,710	1,000 Added 3.57%	29,020 $287,000
Q1 2021 May 17, 2021	SELL	$8.98 - $12.86 $65,015 - $93,106	-7,240 Reduced 20.53%	28,020 $347,000
Q4 2020 Feb 18, 2021	SELL	$5.61 - $13.47 $164,541 - $395,075	-29,330 Reduced 45.41%	35,260 $304,000
Q3 2020 Nov 13, 2020	BUY	$3.33 - $8.26 $215,084 - $533,513	64,590 New	64,590 $436,000

2.13M

93.2K

Ticker KZIA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,111,300
Market Cap $47M
Description
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various...

Get notified when there are updates to the investment portfolio of Truist Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Truist Financial Corp with notifications on news.